POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Potassium chloride provides potassium ions essential for nerve impulse transmission, muscle contraction, and acid-base balance. Sodium chloride provides sodium ions, which are critical for maintaining extracellular fluid volume, osmotic pressure, and electrochemical gradients.
| Metabolism | Potassium and sodium are not metabolized; they are primarily excreted unchanged by the kidneys. |
| Excretion | Potassium: Approximately 90% renal excretion, 10% fecal. Sodium: Excreted renally, >90% under normal conditions. |
| Half-life | Not applicable as potassium and sodium are endogenous ions; distribution and elimination are rapid and depend on renal function and total body stores. |
| Protein binding | Potassium: Negligible (<2%); sodium: Negligible (<5%). |
| Volume of Distribution | Potassium: 0.5-0.6 L/kg (primarily intracellular); sodium: 0.15-0.3 L/kg (primarily extracellular). |
| Bioavailability | Intravenous: 100%; oral: potassium absorption >90%, sodium absorption nearly complete. |
| Onset of Action | Intravenous: immediate within seconds to minutes; oral: onset varies with gastrointestinal absorption, not clinically relevant for replacement. |
| Duration of Action | Duration depends on ongoing losses and renal function; continuous infusion required for sustained effect. |
| Molecular Weight | Potassium chloride: 74.55 Da; Sodium chloride: 58.44 Da |
Intravenous infusion. Potassium chloride 0.3% (3 g/L) and sodium chloride 0.9%: administer at a rate not exceeding 10 mmol/h (0.75 g/h) of potassium, maximum 200 mmol (15 g) per 24 hours. Dose adjusted based on serum potassium and clinical status.
| Dosage form | INJECTABLE |
| Renal impairment | GFR >50 mL/min: no adjustment. GFR 20-50 mL/min: reduce potassium infusion rate by 50%. GFR <20 mL/min: avoid potassium-containing solutions unless severe hypokalemia and close monitoring. |
| Liver impairment | No specific Child-Pugh based dose adjustments for potassium chloride. Use with caution in severe hepatic impairment due to risk of electrolyte disturbances; monitor potassium levels closely. |
| Pediatric use | IV infusion: 0.5-1 mmol/kg/day of potassium, max rate 0.5 mmol/kg/h. Sodium chloride 0.9% as maintenance fluid: 100-150 mL/kg/day for first 10 kg, then 50 mL/kg/day for next 10 kg, then 20 mL/kg/day thereafter. Adjust based on electrolytes and hydration status. |
| Geriatric use | Initiate at lower end of adult dosing. Typical infusion rate: 5-10 mmol/h of potassium, with frequent monitoring of serum potassium and renal function. Maximum 100 mmol/day initially, titrate slowly. Avoid in patients with impaired renal function. |
| 1st trimester | Potassium and sodium chloride infusions are used to correct electrolyte imbalances. No teratogenic effects are expected, as these are normal body constituents. However, excessive administration may cause maternal electrolyte disturbances, leading to potential fetal effects. Use only if clearly needed. |
| 2nd trimester | Similar to T1; no known fetal harm from therapeutic use. Monitor serum electrolytes to avoid imbalances. |
| 3rd trimester | Same as T1/T2; caution in preeclampsia or renal impairment. Avoid fluid overload. No specific teratogenic risk. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Potassium and sodium readily cross the placenta via active transport and diffusion. Levels in fetal circulation are regulated by maternal-fetal gradients. No specific data on transfer rate; considered safe at therapeutic doses. |
| Breastfeeding | Potassium and sodium chloride are endogenous electrolytes present in breast milk. Infusion of these salts in standard doses does not significantly alter milk composition or pose risk to nursing infant. Monitor maternal serum levels to avoid toxicity. |
| Lactation Rating | L1: Compatible |
| Teratogenic Risk | POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% is an electrolyte replacement solution. Potassium and sodium are essential ions with no known teratogenic risk when administered at physiological concentrations. No fetal abnormalities have been reported with appropriate use. However, extreme electrolyte imbalances may pose indirect risks. Category C: not shown to be harmful in animal studies, but no controlled human studies. Use only if clearly needed. |
| Fetal Monitoring | Monitor serum potassium, sodium, chloride, and renal function periodically during prolonged therapy. For intravenous administration, monitor vital signs, ECG, and infusion site. In pregnancy, assess for fluid overload or electrolyte imbalances that may affect fetal well-being. Use with caution in preeclampsia or renal impairment. |
| Fertility Effects | No known adverse effects on fertility. Potassium and chloride are essential for cellular function and are not associated with reproductive toxicity at therapeutic doses. |
■ FDA Black Box Warning
Concentrated potassium chloride solutions (≥2 mEq/mL) must be diluted before use; undiluted administration can cause cardiac arrest. This product contains potassium chloride 0.3% (4 mEq/L) and sodium chloride 0.9% (154 mEq/L) and is a dilute solution, thus not subject to the concentrated solution boxed warning.
| Common Effects | fluid replacement |
| Serious Effects |
HyperkalemiaHypernatremiaSevere renal impairment with oliguria or anuriaElevated serum chloride levelsCellular swelling in conditions like heat cramps (for salt solutions)Concomitant use of potassium-sparing diuretics or ACE inhibitors with potassium chloride
| Precautions | Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia, Monitor serum electrolytes, renal function, and fluid status during prolonged therapy, Rapid infusion may cause cardiovascular overload or hyperkalemia |
| Food/Dietary | No significant food interactions; administered intravenously. Oral potassium or sodium intake should be monitored in context of total body stores and clinical status. |
| Clinical Pearls | This fixed-combination IV solution provides 4 mEq/L potassium (0.3% KCl) and 154 mEq/L sodium (0.9% NaCl). Use cautiously in patients with renal impairment, heart failure, or hyperkalemia. Monitor serum potassium, renal function, and cardiac status. Avoid in patients with severe hyperkalemia or anuria. Do not co-administer with potassium-sparing diuretics or ACE inhibitors without close monitoring. Administer via central or peripheral line; check compatibility with other IV medications. |
| Patient Advice | This solution is given intravenously to replace fluids and electrolytes. · Tell your healthcare provider if you have kidney problems, heart disease, or are taking diuretics or blood pressure medications. · Report symptoms like muscle weakness, irregular heartbeat, or numbness/tingling. · Do not adjust the infusion rate; it is controlled by medical staff. · Notify your nurse if you experience pain, redness, or swelling at the IV site. |
Loading safety data…